Blockade of MGMT expression by O6 benzyl guanine leads to inhibition of pancreatic cancer growth and induction of apoptosis

Santhi D. Konduri, Jonathan Ticku, George C. Bobustuc, Robert M. Sutphin, Jimmie Colon, Beth Isley, Kishor K Bhakat, Srivenugopal S. Kalkunte, Cheryl H. Baker

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose: We sought to determine whether administration of a MGMT blocker, O6-benzyl guanine (O6BG), at an optimal biological dose alone or in combination with gemcitabine inhibits human pancreatic cancer cell growth. Experimental Design: Human pancreatic cancer L3.6pl and PANC1 cells were treated with O6BG, either alone or in combination with gemcitabine, and the therapeutic efficacy and biological activity of these drug combinations were investigated. Results: O6BG sensitized pancreatic cancer cells to gemcitabine. Protein and mRNA expression of MGMT, cyclin B1, cyclin B2, cyclin A, and ki-67 were significantly decreased in the presence of O 6BG. In sharp contrast, protein expression and mRNA message of p21cip1 were significantly increased. Interestingly, O6BG increases p53-mediated p21cip1 transcriptional activity and suppresses cyclin B1. In addition, our results indicate that p53 is recruited to p21 promoter. Furthermore, an increase in p21cip1 and a decrease in cyclin transcription are p53 dependent. The volume of pancreatic tumors was reduced by 27% in mice treated with gemcitabine alone, by 47% in those treated with O6BG alone, and by 65% in those mice given combination. Immunohistochemical analysis showed that O6BG inhibited expression of MGMT and cyclins, and increased expression of p21cip1. Furthermore, there was a significant decrease in tumor cell proliferation and an increase in tumor cell apoptosis. Conclusions: Collectively, our results show that decreased MGMT expression is correlated with p53 activation, and significantly reduced primary pancreatic tumor growth. These findings suggest that O6BG either alone or in combination with gemcitabine may provide a novel and effective approach for the treatment of human pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)6087-6095
Number of pages9
JournalClinical Cancer Research
Volume15
Issue number19
DOIs
StatePublished - Oct 1 2009

Fingerprint

gemcitabine
Guanine
Pancreatic Neoplasms
Apoptosis
Growth
Cyclin B1
Cyclins
Cyclin B2
Cyclin A
Neoplasms
Messenger RNA
Drug Combinations
Tumor Burden
Proteins
Research Design
Cell Proliferation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Konduri, S. D., Ticku, J., Bobustuc, G. C., Sutphin, R. M., Colon, J., Isley, B., ... Baker, C. H. (2009). Blockade of MGMT expression by O6 benzyl guanine leads to inhibition of pancreatic cancer growth and induction of apoptosis. Clinical Cancer Research, 15(19), 6087-6095. https://doi.org/10.1158/1078-0432.CCR-09-0887

Blockade of MGMT expression by O6 benzyl guanine leads to inhibition of pancreatic cancer growth and induction of apoptosis. / Konduri, Santhi D.; Ticku, Jonathan; Bobustuc, George C.; Sutphin, Robert M.; Colon, Jimmie; Isley, Beth; Bhakat, Kishor K; Kalkunte, Srivenugopal S.; Baker, Cheryl H.

In: Clinical Cancer Research, Vol. 15, No. 19, 01.10.2009, p. 6087-6095.

Research output: Contribution to journalArticle

Konduri, SD, Ticku, J, Bobustuc, GC, Sutphin, RM, Colon, J, Isley, B, Bhakat, KK, Kalkunte, SS & Baker, CH 2009, 'Blockade of MGMT expression by O6 benzyl guanine leads to inhibition of pancreatic cancer growth and induction of apoptosis', Clinical Cancer Research, vol. 15, no. 19, pp. 6087-6095. https://doi.org/10.1158/1078-0432.CCR-09-0887
Konduri, Santhi D. ; Ticku, Jonathan ; Bobustuc, George C. ; Sutphin, Robert M. ; Colon, Jimmie ; Isley, Beth ; Bhakat, Kishor K ; Kalkunte, Srivenugopal S. ; Baker, Cheryl H. / Blockade of MGMT expression by O6 benzyl guanine leads to inhibition of pancreatic cancer growth and induction of apoptosis. In: Clinical Cancer Research. 2009 ; Vol. 15, No. 19. pp. 6087-6095.
@article{d98ca4ca963b4573b0df72b6691fb449,
title = "Blockade of MGMT expression by O6 benzyl guanine leads to inhibition of pancreatic cancer growth and induction of apoptosis",
abstract = "Purpose: We sought to determine whether administration of a MGMT blocker, O6-benzyl guanine (O6BG), at an optimal biological dose alone or in combination with gemcitabine inhibits human pancreatic cancer cell growth. Experimental Design: Human pancreatic cancer L3.6pl and PANC1 cells were treated with O6BG, either alone or in combination with gemcitabine, and the therapeutic efficacy and biological activity of these drug combinations were investigated. Results: O6BG sensitized pancreatic cancer cells to gemcitabine. Protein and mRNA expression of MGMT, cyclin B1, cyclin B2, cyclin A, and ki-67 were significantly decreased in the presence of O 6BG. In sharp contrast, protein expression and mRNA message of p21cip1 were significantly increased. Interestingly, O6BG increases p53-mediated p21cip1 transcriptional activity and suppresses cyclin B1. In addition, our results indicate that p53 is recruited to p21 promoter. Furthermore, an increase in p21cip1 and a decrease in cyclin transcription are p53 dependent. The volume of pancreatic tumors was reduced by 27{\%} in mice treated with gemcitabine alone, by 47{\%} in those treated with O6BG alone, and by 65{\%} in those mice given combination. Immunohistochemical analysis showed that O6BG inhibited expression of MGMT and cyclins, and increased expression of p21cip1. Furthermore, there was a significant decrease in tumor cell proliferation and an increase in tumor cell apoptosis. Conclusions: Collectively, our results show that decreased MGMT expression is correlated with p53 activation, and significantly reduced primary pancreatic tumor growth. These findings suggest that O6BG either alone or in combination with gemcitabine may provide a novel and effective approach for the treatment of human pancreatic cancer.",
author = "Konduri, {Santhi D.} and Jonathan Ticku and Bobustuc, {George C.} and Sutphin, {Robert M.} and Jimmie Colon and Beth Isley and Bhakat, {Kishor K} and Kalkunte, {Srivenugopal S.} and Baker, {Cheryl H.}",
year = "2009",
month = "10",
day = "1",
doi = "10.1158/1078-0432.CCR-09-0887",
language = "English (US)",
volume = "15",
pages = "6087--6095",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "19",

}

TY - JOUR

T1 - Blockade of MGMT expression by O6 benzyl guanine leads to inhibition of pancreatic cancer growth and induction of apoptosis

AU - Konduri, Santhi D.

AU - Ticku, Jonathan

AU - Bobustuc, George C.

AU - Sutphin, Robert M.

AU - Colon, Jimmie

AU - Isley, Beth

AU - Bhakat, Kishor K

AU - Kalkunte, Srivenugopal S.

AU - Baker, Cheryl H.

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Purpose: We sought to determine whether administration of a MGMT blocker, O6-benzyl guanine (O6BG), at an optimal biological dose alone or in combination with gemcitabine inhibits human pancreatic cancer cell growth. Experimental Design: Human pancreatic cancer L3.6pl and PANC1 cells were treated with O6BG, either alone or in combination with gemcitabine, and the therapeutic efficacy and biological activity of these drug combinations were investigated. Results: O6BG sensitized pancreatic cancer cells to gemcitabine. Protein and mRNA expression of MGMT, cyclin B1, cyclin B2, cyclin A, and ki-67 were significantly decreased in the presence of O 6BG. In sharp contrast, protein expression and mRNA message of p21cip1 were significantly increased. Interestingly, O6BG increases p53-mediated p21cip1 transcriptional activity and suppresses cyclin B1. In addition, our results indicate that p53 is recruited to p21 promoter. Furthermore, an increase in p21cip1 and a decrease in cyclin transcription are p53 dependent. The volume of pancreatic tumors was reduced by 27% in mice treated with gemcitabine alone, by 47% in those treated with O6BG alone, and by 65% in those mice given combination. Immunohistochemical analysis showed that O6BG inhibited expression of MGMT and cyclins, and increased expression of p21cip1. Furthermore, there was a significant decrease in tumor cell proliferation and an increase in tumor cell apoptosis. Conclusions: Collectively, our results show that decreased MGMT expression is correlated with p53 activation, and significantly reduced primary pancreatic tumor growth. These findings suggest that O6BG either alone or in combination with gemcitabine may provide a novel and effective approach for the treatment of human pancreatic cancer.

AB - Purpose: We sought to determine whether administration of a MGMT blocker, O6-benzyl guanine (O6BG), at an optimal biological dose alone or in combination with gemcitabine inhibits human pancreatic cancer cell growth. Experimental Design: Human pancreatic cancer L3.6pl and PANC1 cells were treated with O6BG, either alone or in combination with gemcitabine, and the therapeutic efficacy and biological activity of these drug combinations were investigated. Results: O6BG sensitized pancreatic cancer cells to gemcitabine. Protein and mRNA expression of MGMT, cyclin B1, cyclin B2, cyclin A, and ki-67 were significantly decreased in the presence of O 6BG. In sharp contrast, protein expression and mRNA message of p21cip1 were significantly increased. Interestingly, O6BG increases p53-mediated p21cip1 transcriptional activity and suppresses cyclin B1. In addition, our results indicate that p53 is recruited to p21 promoter. Furthermore, an increase in p21cip1 and a decrease in cyclin transcription are p53 dependent. The volume of pancreatic tumors was reduced by 27% in mice treated with gemcitabine alone, by 47% in those treated with O6BG alone, and by 65% in those mice given combination. Immunohistochemical analysis showed that O6BG inhibited expression of MGMT and cyclins, and increased expression of p21cip1. Furthermore, there was a significant decrease in tumor cell proliferation and an increase in tumor cell apoptosis. Conclusions: Collectively, our results show that decreased MGMT expression is correlated with p53 activation, and significantly reduced primary pancreatic tumor growth. These findings suggest that O6BG either alone or in combination with gemcitabine may provide a novel and effective approach for the treatment of human pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=70349690451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349690451&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-09-0887

DO - 10.1158/1078-0432.CCR-09-0887

M3 - Article

VL - 15

SP - 6087

EP - 6095

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 19

ER -